Drugs Information:
Tenofovir alafenamide
Basic Information
|
||
ID | DDInter2088 | |
Drug Type | small molecule | |
Molecular Formula | C21H29N6O5P | |
Molecular Weight | 476.474 | |
CAS Number | 379270-37-8 | |
Description | Tenofovir alafenamide is a novel [tenofovir] prodrug developed in order to improve renal safety when compared to the counterpart [tenofovir disoproxil].[A178060] Both of these prodrugs were first created to cover the polar phosphonic acid group on tenofovir by using a novel oxycarbonyloxymethyl linkers to improve the oral bioavailability and intestinal diffusion.[T239] Tenofovir alafenamide is an alanine ester form characterized for presenting low systemic levels but high intracellular concentration.[A178219] It has been reported to produce a large antiviral efficacy at doses ten times lower than tenofovir disoproxil.[A178327] Tenofovir alafenamide is indicated to treat chronic hepatitis B,[L6241] treat HIV-1,[L4388,L6277,L6280,L6283] and prevent HIV-1 infections.[L4388,L9010] Tenofovir alafenamide was developed by Gilead Sciences Inc and granted FDA approval on 5 November 2015.[L6271] | |
ATC Classification | J05AR19 J05AR20 J05AR17 J05AF13 J05AR22 J05AR18 | |
IUPAC Name | propan-2-yl (2S)-2-{[(S)-({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)(phenoxy)phosphoryl]amino}propanoate | |
InChI | LDEKQSIMHVQZJK-CAQYMETFSA-N | |
Canonical SMILES | CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1 | |
Useful Links | DrugBank ChEBI PubChem Substance KEGG Drug ChemSpider Wikipedia ChEMBL ZINC |
Interactions with
Tenofovir alafenamide
Filter:
Severity level | ID | Name | Mechanism | Detail |
---|
Interactions with diseases
Filter:
Severity level | Disease name | Text | References |
---|
Interactions with foods
Filter:
Severity level | Food name | Description | Management | Mechanism | References |
---|
Interactions with compound preparation
Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
---|